Perioperative Treatment of Resectable Liver Metastases (PERIMAX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01540435
Recruitment Status : Withdrawn (insufficient recruitment)
First Posted : February 28, 2012
Last Update Posted : May 29, 2013
University of Halle Medical Faculty
Information provided by (Responsible Party):
Hans J Schlitt, Prof. MD, University of Regensburg

February 16, 2012
February 28, 2012
May 29, 2013
September 2012
May 2013   (Final data collection date for primary outcome measure)
Failure-free survival (FFS@18) [ Time Frame: 18 months ]
Failure will be defined as no R0 resection, local or distant recurrence or death from any cause.
Same as current
Complete list of historical versions of study NCT01540435 on Archive Site
  • Disease Free Survival (DFS) [ Time Frame: 5 years ]
  • Overall survival (OS) [ Time Frame: 5 years ]
  • Perioperative morbidity [ Time Frame: 30 days (hospital stay) ]
  • Quality of life [ Time Frame: 12 months ]
  • Achievability of R0 resection [ Time Frame: intraoperative ]
  • Overall response rate (Arm B) [ Time Frame: 3 months ]
  • Pathologic response rate [ Time Frame: 18 weeks ]
Same as current
Not Provided
Not Provided
Perioperative Treatment of Resectable Liver Metastases
Perioperative FOLFOXIRI and Bevacizumab Compared With Postoperative FOLFOX in Patients With Resectable Liver Metastases From Colorectal Cancer (PERIMAX). A Randomized, Multidisciplinary DGAV(CAO-V/CALGP)/AIO Phase II Trial
This randomized, controlled, multicenter, non-comparative phase II trial compares an intensified perioperative treatment of patients with resectable synchronous or metachronous colorectal liver metastases to primary surgery and adjuvant systemic chemotherapy.

Recurrence rates after R0-resection of colorectal liver metastases are still very high (about 60-70 %). Therefore, multidisciplinary treatment of these patients is frequently used in order to achieve a beneficial impact regarding progression-free and overall survival. The point in time of treatment, pre- and/or postoperative, is still a matter of debate. In the EORTC 40983 trial, perioperative chemotherapy with 5-Fluorouracil and oxaliplatin (FOLFOX-Regimen) displayed a non-significant benefit in 3 year disease free survival in the intent to treat population (HR 0.79, 95% CI 0.62 to 1.02) (Nordlinger, Sorbye et al. 2008). The combined analysis of two adjuvant trials, with a (non-contemporary) 5-FU Bolus regimen, showed a non-significant prolongation of median disease free survival (DFS) from 18.8 to 27.9 months (p=0.058) and OS from 47.3 to 62.2 months (p=0.095) (Mitry, Fields et al. 2008). However, postoperative treatment with 6 months of FOLFOX is often used in daily practise. Thus, further investigation is urgently warranted.

This phase II trial evaluates two strategies with intensified perioperative or postoperative treatment regimens. Current studies established the role of the FOLFOXIRI regimen in the metastatic setting (Falcone, Ricci et al. 2007). A further intensification of a three drug regimen with bevacizumab seem to be feasible yielding response rates up to 84% and a disease control rate up to 100% (Falcone 2008; Bruera, Santomaggio et al. 2010; Masi, Loupakis et al. 2010). Regarding the efficacy, evaluation of FOLFOXIRI and bevacizumab in preoperative treatment for resectable CLM seems to be promising. Postoperative treatment with FOLFOX for 6 months was chosen for arm A.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Colon Cancer Liver Metastasis
Drug: Bevacizumab
Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
Other Name: VEGF antibody
  • No Intervention: Postoperative Arm (Arm A)


    Oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)

    Duration of treatment:

    Treatment will be administered for 12 cycles (6 months) postoperatively starting 6 weeks after surgery.

  • Experimental: Perioperative Arm (Arm B)

    Therapy will be administered in a biweekly schedule. First preoperative cycle will be administered with 75% of dosage for FOLFOXIRI, if no diarrhea ≥ grade 3 occurs, following cycles should be administered in full dosage.

    FOLFOXIRI + bevacizumab:

    bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)

    Duration of treatment:

    Treatment will be administered for 6 cycles (3 months) preoperatively (last cycle without bevacizumab), after 6 weeks followed by liver surgery, after further 6 weeks followed by 6 cycles (3 months) postoperatively.

    Intervention: Drug: Bevacizumab
Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt HJ, Schmoll HJ. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer. 2012 Aug 16;12:356. doi: 10.1186/1471-2407-12-356. Review.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2013
May 2013   (Final data collection date for primary outcome measure)

Main selection criteria:

  1. Histological proven CRC with completely resectable metachronous or synchronous liver metastases (as judged by the treating surgeon).
  2. Patients must have undergone complete resection (R0) of the primary tumor at least 4 weeks before randomization. Or in case of synchronous disease with intact primary; the primary tumor have to be R0 resectable together with the liver metastases and the patient has a non-obstructive primary tumor and is able to receive preoperative chemotherapy before surgery. Synchronous rectal primary is not allowed.
  3. Measurable hepatic disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
  4. No evidence of extra-hepatic metastasis of CRC.
  5. Patients must be from 18 to 75 years.
  6. ECOG Performance status ≤ 1
  7. No previous chemotherapy for metastatic disease. Radiotherapy alone is allowed if given pre or post protocol treatment.
  8. Previous adjuvant chemotherapy for primary CRC is allowed if completed at least 6 months before inclusion in this study.
  9. All the following tests should be done within 4 weeks prior to randomization

    • Absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L, and hemoglobin > 9 g/dL or 5.59 mmol/l.
    • Serum creatinine less than 1.5 times the upper limit of normal (ULN) (to exclude severe renal impairment); no significant proteinuria (urine dipstick for proteinuria ³ 2+. If urine dipstick is ³ 2+, 24-hour urine must demonstrate £ 1 g of protein in 24 hours for patient to be eligible).
    • Absence of major hepatic insufficiency (bilirubin < 1.5 x ULN and aspartate aminotransferase (ASAT)/alanine aminotransferase (ALAT) < 5 x ULN).
    • Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and aPTT < 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of registration.
  10. No pregnancy or breast feeding. Negative serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women < 1 year after the onset of menopause is required before entering in the trial. Note: a negative test has to be reconfirmed by a urine test, should the 7-day window be exceeded.
  11. Adequate contraception is required during and for 3 months after study treatment for both male and female patients if the risk of conception exists.
  12. No major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to randomization.
  13. No previous exposure to VEGF/VEGFR-targeting therapy within the last 12 months.
  14. No thrombosis or severe bleeding within 6 months prior to entry into the study (except for bleeding of the tumor before its surgical resection) and no evidence of bleeding diathesis or coagulopathy.
  15. Absence of peripheral neuropathy NCI CTCAE-grade ≥ 1, active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as > 4 loose stools per day), serious wound complications, ulcers, or bone fractures.
  16. No evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
  17. No concomitant treatment with ASS > 325 mg or NSAIDs, known to inhibit platelet function, sorivudin or analog compounds or preparations of St. John's wort.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
2010-023575-25 ( EudraCT Number )
Not Provided
Not Provided
Hans J Schlitt, Prof. MD, University of Regensburg
University of Regensburg
University of Halle Medical Faculty
Study Chair: Hans J. Schlitt, Prof. MD Department of Surgery, University Medical Center Regensburg
Study Director: Hans-Joachim Schmoll, Prof. MD Department of Internal Medicine IV, University Hospital Halle
University of Regensburg
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP